Biodexa Pharmaceuticals PLC (BDRX)
4.40
+0.55
(+14.29%)
USD |
NASDAQ |
Nov 21, 16:00
4.19
-0.21
(-4.77%)
After-Hours: 05:21
Biodexa Pharmaceuticals Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| December 31, 2020 | 0.0159 |
| June 30, 2020 | 0.7022 |
| December 31, 2019 | 0.2524 |
| June 30, 2019 | 0.0442 |
| Date | Value |
|---|---|
| December 31, 2018 | 0.0592 |
| June 30, 2018 | 0.2858 |
| December 31, 2017 | 0.1868 |
| June 30, 2017 | 0.0482 |
| December 31, 2016 | 0.0454 |
| June 30, 2016 | 0.0442 |
| December 31, 2015 | 0.0386 |
| June 30, 2015 | 0.0456 |
| December 31, 2014 | 0.0463 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2021
0.7022
Maximum
Jun 2020
0.1078
Average
--
Median
Jun 2021
Debt to Equity Ratio Benchmarks
| Adaptimmune Therapeutics PLC | 0.6234 |
| Verona Pharma PLC | 0.9197 |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | -- |
| TC BioPharm (Holdings) PLC | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 17.67M |
| Total Liabilities (Quarterly) | 6.628M |
| Shareholders Equity (Quarterly) | 11.04M |